SCHEMBL248683

SCHEMBL248683

O=c1nc(NCc2ccccc2)cc[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.50
APP P05067 1/20 0.49
FABP1 P07148 1/20 0.49
FABP6 P51161 1/20 0.49
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
HCAR2 Q8TDS4 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HSD17B10 Q99714 1/20 0.46
RECQL P46063 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554284 0.85 ELANE (0.51) ELANEAPPKDM4EL3MBTL1MEN1
SCHEMBL12336997 0.83 KDM4E (0.47) KDM4EGAAL3MBTL1HSD17B10MEN1
SCHEMBL14243750 0.82 CYP1A2 (0.55) L3MBTL1HSD17B10MEN1ALDH1A1HPGD
SCHEMBL413320 0.79 LMNA (0.47) FABP1FABP6HCAR2KDM4ELMNA
SCHEMBL2035523 0.79 MEN1 (0.48) LMNAGAAMEN1KMT2A
SCHEMBL9136615 0.77 CYP1A2 (0.35) ELANEAPPJAK2JAK1HCAR2
SCHEMBL2460687 0.77 NPC1 (0.57) APPJAK2KDM4EGAAHSD17B10
SCHEMBL2341198 0.77 HSD17B10 (0.57) KDM4ELMNAL3MBTL1HSD17B10MEN1
SCHEMBL17390720 0.76 ROCK2 (0.53) HSD17B10MEN1ALDH1A1KMT2A
SCHEMBL5057920 0.76 FABP1 (0.53) FABP1FABP6HCAR2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746918-A1 METHODS OF PREPARING SURFACE MODIFIED VIRAL CAPSIDS Borea Therapeutics S.r.l. (IT) 2026-05-27 EP claimed
WO-2026101423-A1 PHOTOSWITCHABLE CHEMICAL INDUCED DIMERIZATION SYSTEMS FOR CONTROL OF CELLULAR ACTIVITIES WITH LIGHT WU YAOWEN (SE) 2026-05-15 WO claimed
WO-2026102435-A1 METHODS OF NUCLEIC ACID PROCESSING AND SYNTHESIS UNIVERSITY OF MASSACHUSETTS (US) 2026-05-15 WO claimed
WO-2026085618-A1 METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION YYZ PHARMATECH INC. (CA) 2026-04-30 WO claimed
EP-4716533-A2 FLUORESCENT INDICATORS FOR METAL ION DETECTION AS SUBSTRATES FOR A SELF-LABELING ENZYME Ion Biosciences (US) 2026-04-01 EP claimed
US-12560608-B2 Detection of molecular associations CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2026-02-24 US claimed
EP-4688872-A1 CLICK-TO-INSTALL GENOME EDITING The General Hospital Corporation (US) 2026-02-11 EP claimed
US-20250377301-A1 STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE FREISTAAT BAYERN LUDWIG MAXIMILIANS UNIV MUENCHEN (DE) 2025-12-11 US claimed
US-20250333696-A1 DNA-CHIMERIC ANTIGEN RECEPTOR T CELLS FOR IMMUNOTHERAPY UNIV ARIZONA STATE (US) 2025-10-30 US claimed
US-20250326723-A1 Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly UNIV NORTHWESTERN (US) 2025-10-23 US claimed
WO-2010046067-A1 IMPROVED ALLELE-SPECIFIC AMPLIFICATION ROCHE DIAGNOSTICS GMBH (DE) 2010-04-29 WO claimed
US-20100099110-A1 Allele-Specific Amplification ROCHE MOLECULAR SYSTEMS, INC. (US) 2010-04-22 US claimed
WO-2010012962-A2 METHOD FOR DETECTING MEMBRANE PROTEIN INTERNALIZATION CIS-BIO INTERNATIONAL (FR) 2010-02-04 WO claimed
WO-2009060065-A1 METHOD OF QUANTIFYING TRANSIENT INTERACTIONS BETWEEN PROTEINS COVALYS BIOSCIENCES AG (CH) 2009-05-14 WO claimed
EP-2049499-A1 LABELLING OF FUSION PROTEINS WITH SYNTHETIC PROBES EPFL Ecole Polytechnique Fédérale de Lausanne (CH) 2009-04-22 EP claimed
EP-1895840-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES Inspire Pharmaceuticals, Inc. (US) 2008-03-12 EP claimed
WO-2008012296-A1 LABELLING OF FUSION PROTEINS WITH SYNTHETIC PROBES EPFL - ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2008-01-31 WO claimed
EP-1882688-A1 Labelling of fusion proteins with synthetic probes EPFL Ecole Polytechnique Fédérale de Lausanne (CH) 2008-01-30 EP claimed
US-20070015726-A1 P2Y6 receptor agonists for treating lung diseases MERCK SHARP & DOHME LLC 2007-01-18 US claimed
WO-2007002945-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES INSPIRE PHARMACEUTICALS, INC. (US) 2007-01-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015726-A1 P2Y6 receptor agonists for treating lung diseases P2RY6, P2RY1, P2RY11 ELANE 677/4885APP 4550/4885FABP1 2436/4885
US-20250377301-A1 STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE CRY1, MKI67, IK ELANE 3299/4885APP 1521/4885FABP1 2541/4885
US-12560608-B2 Detection of molecular associations APP, SPPL2A, SPPL2B ELANE 2877/4885APP 1/4885FABP1 618/4885
US-20100099110-A1 Allele-Specific Amplification RNGTT, HLA-C, POLL ELANE 410/4885APP 4316/4885FABP1 3475/4885
US-20250326723-A1 Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly CRABP2, RARB, RARA ELANE 4471/4885APP 3978/4885FABP1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.